AKT1 and cancer: It has also been reported previously that resistance to some anticancer drugs in cancer cells can be decreased by inhibiting the Ras/Raf/MEK/ERK and PI3K/AKT pathways 31, 32 and key transcription factors, such as NF‐κB and HIF‐1α 7.